Ease Transportation
Opioid treatment clinics get 45 days for delivered meds
DEA says the longer clock can ease transportation and scheduling problems when a pharmacy sends a covered controlled substance to a registered clinic.
The rule keeps those drugs tied to the named patient, but gives clinics more time to administer them after delivery. DEA says the change can help fill gaps in treatment access.
- Pharmacy-delivered MAT drugs now have 45 days to be administered, up from 14.
- DEA says the longer window can cut transportation and scheduling burdens.
- The change applies only to covered deliveries at a practitioner’s registered location.
- The Drug Enforcement Administration, a federal agency, has given patients and clinics using medication-assisted treatment (MAT) for opioid use disorder a longer runway
- When a pharmacy delivers a covered controlled substance to a practitioner’s registered location, the medication now has 45 days, not 14, to be administered to the named patient
The Drug Enforcement Administration, a federal agency, has given patients and clinics using medication-assisted treatment (MAT) for opioid use disorder a longer runway. When a pharmacy delivers a covered controlled substance to a practitioner’s registered location, the medication now has 45 days, not 14, to be administered to the named patient.
That matters because treatment does not happen on paper. Clinics have to line up deliveries, appointments and staff time, and patients have to get back to the site when the dose is ready. DEA says the extra time can reduce transportation costs and other access burdens.
Why the extra time matters
The rule is meant to smooth out a practical problem: a medication can arrive on time but still miss the window if a patient cannot get back quickly enough or a clinic has trouble coordinating schedules. The longer clock gives treatment sites more breathing room without changing the underlying treatment.
DEA describes the change as one more step in filling gaps in MAT access. The agency has also pointed to the pharmacy-delivery setup as a way to make maintenance or detoxification treatment easier to manage when the statute’s conditions are met.
What stays narrow
This is not a blanket change for every prescription or every practitioner. It applies only when the drug is delivered by a pharmacy to a practitioner’s registered location and administered under the limits Congress set out in the SUPPORT Act, the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018.
The old 14-day deadline has simply been replaced with 45 days in that narrow lane. The result is less logistical pressure for some treatment programs, not a wholesale rewrite of opioid policy.